Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World (RINCOVID)

Centre d'Expertise sur l'Altitude EXALT

Status: Unknown

Conditions: Covid19; High Altitude

Treatments: Diagnostic Test: SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)

Study type: Observational

Funder types: Other

Identifiers

NCT04604249

RINCOVID

Details and patient eligibility

About

Since the beginning of 2020, SARS-CoV-2 outbreak spread over the world, conducting in a pandemic state declared by the world health organization in March 2020. Conflicting data have been yet published regarding to the incidence rate of COVID-19 infection in altitude. Mainly based on analysis from national Peru database, some authors argued that COVID-19 disease, as well as case fatality rate was less frequent in altitude. However, epidemiological data are lacking regarding to the prevalence of COVID-19 in altitude, and more specially in high altitude.

Aim of this cross-sectional study is to assess the prevalence of seroconversion for the SARS-CoV-2 in the population of La Rinconada, a mining town at 5,100 m, the highest city in the world.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age > 18 years.

Exclusion criteria

• Age < 18 years.
• Inability to give informed consent.